UK’s MHRA allows early access to lumasiran for ultra-rare disease
Lumasiran targets primary hyperoxaluria type 1 (PH1), which affects just around 90 people in the UK and one to three individuals per million in Europe
Read More
Tag: primary hyperoxaluria type 1
Alynlam completes EU, US filings for lumasiran
If approved, lumasiran would be the first approved therapeutic treatment option for primary hyperoxaluria type 1
Read More
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
